

Comunidad de Madrid





AUDITORIO HOTEL MELIÁ CASTILLA. MADRID. SPAIN, APRIL 26th – 27th 2007











www.cardiovascularcelltherapy.com

ACREDITATION Director **Co-directors International Scientific Committee ORGANIZATION Executive Local Committee** Web site and Educational Program Committee **Organizators EDUCATIONAL OBJECTIVES** General learning objectives Workshop objectives **FACULTY SCIENTIFIC AGENDA Meeting Venue** Official languages **GENERAL INFORMATION Technical Secretariat Scientific Secretariat** WEB SITE AND EDUCATIVE MATERIAL **COLLABORATORS AND SPONSORS INDICE**



www.cardiovascularcelltherapy.com

Spanish Society of Cardiology.

Spanish Society of Cardiology. Continuing Medical Education Accreditation Program.



European **B**oard for **A**creditation in **C**ardiology

2

ORGANIZATION

Director

Francisco Fernández-Avilés

Department of Cardiology Hospital General Universitario Gregorio Marañón (Madrid)

Co-directors

José Alberto San Román

Instituto de Ciencias del Corazón (ICICOR). Hospital Clínico-Universitario de Valladolid

Ana Sánchez

Departamento de Fisiología. Instituto de Biología y Genética Molecular IBGM Facultad de Medicina. Universidad de Valladolid.

Pedro L. Sánchez

Department of Cardiology Hospital General Universitario Gregorio Marañón (Madrid)

International Scientific Advisory Board

Jozef Bartunek (Aalst, Belgium)

Nabil Dib (Phoenix, USA)

Stephanie Dimmeler (Frankfurt, Germany)

Helmut Drexler (Hannover, Germany)

Mª Eugenia Fernández Santos (Valladolid, Spain)

Valentín Fuster (New York, USA)

Manuel Galiñanes (Leicester, United Kingdom)

Eulogio García (Madrid, Spain)

Javier García-Sancho (Valladolid, Spain)

Bernard Gersh (Rochester, USA)

Andrés Iñiguez (Vigo, Spain)

Juan Carlos Izpisúa (La Jolla, USA)

Stefan Janssens (Leuven, Belgium)

Anthony Mathur (London, United Kingdom)

John Martin (London, United Kingdom)

Philippe Menasche (Paris, France)

Bernardo Nadal - Ginard (New York, USA)

Emerson Perin (Houston, USA)

Sylvia Priori (Pavia, Italy)

Antonio Serra (Barcelona, Spain)

Patrick W. J. Serruys (Rotterdam, The Netherlands)

Jordi Soler Soler (Barcelona, Spain)

Warren Sherman (New York, USA)

Doris Taylor (Minneapolis, USA)

Michal Tendera (Katowice, Poland)

William Wijns (Aalst, Belgium)

Andreas Zeiher (Frankfurt, Germany)

a

Executive Local Committee

Jaime Elizaga

(Hospital General Universitario Gregorio Marañón)

Julio Osende

(Hospital General Universitario Gregorio Marañón)

Website and Educational

Program Committee

José Antonio Serrano

(Hospital General Universitario Gregorio Marañón)

Ricardo Sanz

(Hospital General Universitario Gregorio Marañón)

Organization

- Department of Cardiology.
 Hospital General Universitario Gregorio Marañón
- Department of Cardiac Surgery.
 Hospital General Universitario Gregorio Marañón
- Department of Haematology.
 Hospital Universitario Río Hortega. Valladolid.
- Department of Haematology.
 Hospital General Universitario Gregorio Marañón
- Instituto de Ciencias del Corazón (ICICOR)
 del Hospital Clínico-Universitario de Valladolid
- Red Temática de Investigación Cardiovascular del Instituto de Salud Carlos III (RECAVA)
- Grupo de Terapia Celular Aplicada al Miocardio
 (TECAM, Hospital Clínico-Universitario de Valladolid,
 Hospital Universitario Río Hortega, Instituto
 de Biología y Genética Molecular)
- Task Force on Stem Cell Regeneration of the Heart (European Society of Cardiology)

General learning objectives

This symposium is aimed at both medical and non-medical scientists interested in the study and application of gene and stem cell therapy for the prevention and treatment of heart failure and other cardiovascular diseases. For this reason the audience comprises:

- a) Preclinical researchers from all areas wishing to deepen their knowledge of cardiovascular developments, the mechanisms of progenitor cells in the maintenance and repair of cardiovascular structures, or in the identification, purification, and production processes of stem cells with therapeutic potential.
- **b)** Doctors specialising in the care of patients suffering from cardiovascular diseases, and who are interested in finding out about and discussing the current state of affairs and the future prospects for the application of this new therapeutic method.
- c) Surgeons or doctors involved in interventions dedicated to cardiovascular pathology and who are interested in the results and perspectives of gene vehiculization techniques, the stimulation of endogenous progenitors, or cell transplant to the cardiovascular system to fight cardiovascular disease.
- d) Medical or no medical professionals interested in the development of units and networks aimed at the translation of cardiovascular knowledge from bench to bedside and vice versa.
- Medical or no medical professionals interested in envisaging the opportunities for competition of gene and cell therapies in the cardiovascular field.





- 1. Knowedge and ability to discuss the latest advances in the role of progenitor cells in the integrity of the cardiovascular system of a healthy individual.
- 2. Knowedge and and ability to discuss the latest experimental advances in the renewal and repair capacity of the damaged cardiovascular structure via the transplant of adult or embryonic stem cells, the stimulation of endogenous progenitors, or the vehiculization of mitosis-promoting genes.
- 3. Know about and be able to objectively debate the current state of feasibility and safety with regards to the clinical application of genetic stimulation techniques and the transplant of different types of progenitor cells via catheters or surgery.
- 4. Knowedge and ability to debate objectively on the efficiency of these types of treatment in patients with acute or chronic cardiovascular diseases which could be subsidiary.
- 5. Ability to predict the future and the possibilities of scientific and professional attitude with regard to offering these therapeutic methods.
- **6.** Ability to evaluate and decide one's own ability to participate in the application of these therapies for healthcare, clinical, and preclinical purposes.
- **7.** Ability to identify those institutions and groups with the highest performance capabilities in this field, and be able to establish contacts for educational, scientific, and healthcare purposes.

Workshop Objectives

After the general session of the first day, a series of simultaneous workshops will be held to bring outstanding experts and a very restricted audience (no more than 25 people) to discuss in detail conceptual issues and seminal aspects of preclinical and clinical stem cell-based therapies for cardiovascular applications. The overview, accreditation and specific learning objectives of these educational activities can be seen in the introduction to each workshop.

Piero Anversa (New York, USA)

Roman Arnold (Valladolid, Spain)

Jozef Bartunek (Aalst, Belgium)

Antoni Bayes-Genis (Barcelona, Spain)

Javier Bermejo Thomas (Madrid, Spain)

Hector Bueno Zamora (Madrid, Spain)

Noel Caplice (Cork, Ireland)

Nabil Dib (Phoenix, USA)

Javier Díez Martínez (Pamplona, Spain)

Stefanie Dimmeler (Frankfurt, Germany)

Valentín Fuster (New York, USA)

Eulogio García (Madrid, Spain)

David García-Dorado (Barcelona, Spain)

Jonathan Hill (London, United Kingdom)

Dara Kraichman (Baltmore, USA)

Miguel Angel García-Fernández (Madrid, Spain)

Bernard Gersh (Rochester, USA)

Francisco Gracia (Madrid, Spain)

L. C. Guarita Souza (Parana, Brazil)

Juan Carlos Izpisúa (La Jolla, USA)

Stefan Janssens (Leuven, Belgium)

Jacob Joseph (Boston, USA)

Hyu Soo Kim (Seoul, Republic of Korea)

Antoine Lafont (Paris, France)

Patricia Lemarchand (Nantes, France)

Ketil Lunde (Oslo, Norway)

Thomas F. Lüscher (Zurich, Switzerland)

John Martin (Londres, United Kigdom)

Alfredo Martínez (Madrid, Spain)

Manuel Martínez-Sellés (Madrid, Spain)

Philippe Menasche (Paris, France)

Bernardo Nadal-Ginard (New York, USA)

Christoph Nienaber (Rostock, Germany)

Julio Osende (Madrid, Spain)

Esther Pérez-David (Madrid, Spain)

Emerson Perin (Houston, USA)

Felipe Prosper (Pamplona, Spain)

Alberto San Román (Valladolid, Spain)

Ana Sánchez (Valladolid, Spain)

Fermín Sánchez Guijo (Salamanca, Spain)

Gines Sanz (Barcelona, Spain)

Patrick W. Serruys (Rotterdam, The Netherlands)

Jordi Soler Soler (Barcelona, Spain)

Doris Taylor (Minneapolis, USA)

André Terzic (Rochester, USA)

Danielle Torella (Cattanzaro, Italy)

Marco Valgimigli (Ferrara, Italy)

Adolfo Villa (Valladolid, Spain)

Renu Virmani (Gaithesbourg, USA)

Wojciech Wojakowski (Katowice, Poland)

Raquel Yotti (Madrid, Spain)

Agustin Zapata (Madrid, Spain)

Andreas Zeiher (Frankfurt, Germany)

10.30-11.00

Coffee Break

THURSDAY, 26th APRIL 2007

7:45-8:30	REGISTRATION	
•	AUDITORIUM	
8:30-9:00	WELCOMING	
9:00-9:20	COMMEMORATIVE LECTURE	
	Chairpersons:	
	Francisco Gracia (Director ISCIII, Madrid)	
	"The germinal corpuscles of Santiago Ramon y Cajal. A stem cell vision 100 years ago"	
	Alfredo Martinez (Madrid, Spain)	
9:20-9:40	SPECIAL LECTURE	
	Chairpersons:	
	Francisco Gracia (Director ISCIII, Madrid)	
	"Genes, cells, imaging, molecules. Are we entering into the biological golden age of	
	cardiovascular medicine?	
	Valentin Fuster (New York, USA)	
9:45-10:30	OPENING SESSION:	
	Chairpersons:	
	Jordi Soler-Soler (Barcelona, Spain)	
	Gines Sanz (Barcelona, Spain)	
9.45-10:05	"From the cell to the tissue. Lights and shadows of stem cell-based cardiovascular repair.	
	A preclinical view"	
	Doris Taylor (Minneapolis, USA)	
9:05-10:25	"From the bench to the patient. Is preclinical evidence translatable to the clinical arena?"	
	Bernard Gersh (Rochester, USA)	
	The state of the s	

AUDITORIUM

11.00-13:30	PRECLINICAL SESSION
	Chairpersons:
	Ana Sánchez (Valladolid, Spain)
	Julio Osende (Madrid, Spain)
11:00-11:15	"Cellular transplantation for the treatment of non-ischemic dilated cardiomyopathies"
	LC Guarita-Souza (Parana, Brasil)
11:15-11:30	"New cells for new purposes. Use of gingival fibroblast for arterial wall repair"
	Antoine Lafont (Paris, France)
77.00.77.45	
11:30-11:45	"Pleiotropic effects of cytokines on left ventricular remodelling and cardiovascular stem cell therapy"
	Wojciech Wojakowski. (Katowice, Poland)
11:45-12:00	"Skeletal myoblasts for cardiac regeneration in animal models"
	Felipe Prosper. (Pamplona, Spain)
12:00-12:15	"Skeletal myoblasts alter myocardial infarction and inductibility of ventricular arrhythmias"
	Patricia Lemarchand (Nantes, France)
12:15-12:30	"Idiopathic dilated cardiomyopathy exhibits defective vascularization and
12/13/12/30	vessel formation"
	Antoni Bayes-Genis (Barcelona, Spain)
12.30-12:45	Discussant
	Christoph Nienaber (Rostock, Germany)
12.45-13:30	Panel discussion
13.30-15:00	Lunch


AUDITORIUM

15.00- 17:30	CLINICAL SESSION		
	Chairpersons:		
	Alberto San Román (Valladolid, Spain)		
	Manuel Martinez Sellés (Madrid, Spain)		
15.00-15:15	"Autologous bone marrow stem cell mobilization induced		
	by granulocyte colony-stimulating factor after myocardial infarction"		
	Marco Valgimigli (Ferrara, Italy)		
15:15-15:30	"Safety and effectiveness of granulocyte-colony stimulating factor in advanced chronic heart failure" Jacob Joseph (Boston, USA)		
15:30-15:45	"Intracoronary injection of mononuclear bone marrow cells after ACUTE myocardial infarction" Ketil Lunde (Oslo, Norway)		
15:45-16:00	"Intracoronary injection of mononuclear bone marrow cells after ACUTE and OLD myocardial infarction"		
	Andreas Zeiher (Frankfurt, Germany)		
16:00-16:15	"Intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating		
	factor in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES trial"		
	Hyo-Soo Kim (Seoul, Republic of Korea)		
16:15-16:30	"Long-term follow-up of the first patients with ischemic heart failure and skeletal myoblast transplantation"		
	Philippe Menasché (Paris, France)		
16:30-16:45	"Myoblast in the clinical scenario. Is the USA experience different?"		
	Nabil Dib (Phoenix, USA)		
16:45-17:00	Discussant		
	Stefanie Dimmeler (Frankfurt, Germany)		
17.00-17:30	Panel discussion		

FRIDAY, 27th APRIL 2007

•	AUDITORIUM
9:00 - 11:00	KEYNOTE SESSION
	Chairpersons:
	Hector Bueno (Madrid, Spain)
	Stefan Janssens (Leuven, Belgium)
9:00-9:20	"Cell processing protocol for myocardial repair. Is this the clue for positive results?"
	Stefanie Dimmeler (Frankfurt, Germany)
9.20-9:40	"Stem cell therapy for myocardial repair. Size matters?"
	Bernardo Nadal-Ginard (New York, USA)
9:40-10:00	"Stem cell attraction to accelerate reendothelization process. Is this the future of
	drug eluting stents?"
	Patrick W. Serruys (Rotterdam, The Netherlands)
10.00-10:20	"From Genes to metabolical products. Biological bases of individualized cardiovascular
	prevention and therapy"
	Andre Terzic (Rochester, USA)
10:20-10:40	"From fishes to mamarians. Is regeneration of adult myocardium possible?"
	Juan Carlos Izpisúa (La Jolla, USA)
10:40-11:00	"Myocardial repair: are the reasons for scepticism biological, methodological or both?"
	Piero Anversa (New York, USA)
11:00-11:30	Panel Discussion
11:30-12:00	Coffee Break

12.00-12:30	CARDIAC STEM CELL THERAPY CONTROVERSY		
	"Lights and shadows stem cell therapy. Are we running too fast?" Chairpersons:		
	David García-Dorado (Barcelona, Spain)		
	Miguel Angel García-Fernandez (Madrid, Spain)		
	"MYOCARDIAL REGENERATION IN ANIMAL MODELS. REALITY OR FANTASY"		
12.00-12.15	PRO		
	Bernardo Nadal-Ginard (New York, USA)		
12.15-12.30	CONTRA		
	Renu Virmani (Gaithersbourg, USA)		
	"STEM CELL THERAPY FOR STEMI. IS IT TIME FOR A LARGE SCALE CLINICAL TRIAL?"		
12:30-12:45	PRO		
	Andreas Zeiher (Frankfurt, Germany)		
12:45-13:00	CONTRA		
	Philippe Menasché (Paris, France)		
13.00-13.30	Panel Discussion		
13.30-15.00	Lunch		



LIVE CASE RETRANSMISSION

15.00-16.00	STEM CELL DELIVE	STEM CELL DELIVERY THROUGH THE GREAT VENOUS SYSTEM		
	Case operator:	Tomasz Siminiak (Poznan, Poland)		
	Discussants:	Emerson Perin (Houston, USA)		
		Eulogio García (Madrid, Spain)		
16.00-17:00	CLOSING SESSION			
	"Dreams and reality for the future"			
	Chairpersons:			
		John Martin (London, United Kingdom)		
		Agustín Zapata (Madrid, Spain)		
16:00-16:20	"Stem cell delivery f	for cardiovascular repair. How will we do it five years from now?"		
	Bernardo Nadal-Ginard (New York, USA)			
16:20-16:40	"Diseases or individu	uals. Will advances in biology personalise cardiovascular medicine?"		
	Thomas F. Lüscher (Zurich, Switzerland)			
16:40-16:50	Message for the fut	rure.		
	John Martin (London, United Kingdom)			
16:50-17:00	Adjourn			
	Francisco Fernandez-Aviles			

6

GENERAL INFORMATION

Meeting Venue

Auditorio Hotel Meliá Castilla C/ Capitán Haya, 43 28020 Madrid (Spain)

Date

26th and 27th April 2007



Official Languages

English and Spanish (simultaneous translation will be available)

Scientific Secretariat

Ana Mª Fernández Baza Hospital General Universitario Gregorio Marañón C/ Doctor Esquerdo 46 47005 Valladolid

tf. 00 34 91 426 58 82 fx. 00 34 91 586 82 76

anafdezbaza@cardiovascularcelltherapy.com

Technical Secretariat

Viajes Orbiazul C/Alonso Pesquera 2 47002 Valladolid tf. 00 34 983 30 91 22 fx. 00 34 983 29 53 51

housing@cardiovascularcelltherapy.com

7

WEB SITE AND EDUCATIONAL PRODUCTS

<u>www.cardiovascularcelltherapy.com</u> is a virtual site which contains all the information related to the Symposium and its previous editions.

It is possible through this web-site to access the scientific program, to register and to reserve accommodation.

It is also a priority for this web site to offer updated information about Stem Cell Therapy for Cardiovascular Diseases, so that appropriate access to the related sites has been created. High quality educational material such as access to web casts, conferences, or updated bibliography is also accessible through this web site.

